(1) A pharmacist shall conduct a prospective drug utilization review ("DUR") before each new prescription or medication order is dispensed or delivered to a patient or a patient's agent. The DUR may include a review of computerized alerts, the patient record, and each new and renewed prescription or medication order for the purpose of promoting therapeutic appropriateness, by making a reasonable effort to identify the following:

1. (a) over-utilization or under-utilization;
2. (b) therapeutic duplication;
3. (c) drug-disease contraindication;
4. (d) drug-drug interaction;
5. (e) drug-food interaction;
6. (f) incorrect drug dosage or duration of drug treatment;
7. (g) drug-allergy interactions;
8. (h) abuse or misuse;
9. (i) any significant change in drug, dose, or directions; and
10. (j) any age related contraindications.

(3) The DUR shall be based upon current standards which may include the following:

1. (a) the American Hospital Formulary Service Drug Information;
2. (b) the United States Pharmacopoeia Drug Information;
3. (c) the American Medical Association Drug Evaluations;
4. (d) Plumb's Veterinary Drug Handbook; and
5. (e) other peer-reviewed medical literature.